No ASX ETF holds Dimerix (DXB) as of 15 Oct 2026. Over the last year it fell 60.4%: on $10,000, −$6038. We explain 5 big moves in that time.
About DXB
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$132.1m
- Held by0 ETFs
- Big moves5 in 1Y
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
Why it moved
- +16.3%2 Jul 2026· Sector Flow
Unclear specific catalyst; Dimerix shares moved on heightened small-cap biotech/sector interest rather than company-specific news.
- +10.5%19 Jun 2026· Contract
Dimerix announced a major Asian licensing deal for DMX-200, worth up to A$481 million, driving shares up.
- +21.2%16 Jun 2026· Contract
Dimerix announced a major Asian licensing deal with Everest Medicines for DMX-200 valued up to A$481 million, driving the stock up over 20%.
- −38.5%28 Apr 2026· Operational
Dimerix's Phase 3 kidney disease drug trial (ACTION3) progress update was interpreted as a 'de-risking' move, likely disappointing investors who expected more definitive efficacy data, triggering a sharp sell-off.
- −14.4%24 Dec 2025· Sector Flow
Shares fell despite positive news about Dimerix's US licensing agreement and BioMarin's acquisition of Amicus, likely due to profit-taking or concerns over deal implications.
Held by 0 ETFs
No ETF we track holds DXB directly.
Other Health Care companies
- SHLSonic Healthcare47 ETFs
- RMDResMed44 ETFs
- CSLCSL Limited42 ETFs
- BDXBcal36 ETFs
- CSXCleanspace36 ETFs
- REGRegis Health33 ETFs
- TLXTelix Pharma32 ETFs
- SIGSigma Healthcare31 ETFs